{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:23:12Z","timestamp":1767856992036,"version":"3.49.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.nucmedbio.2011.10.020","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T14:14:13Z","timestamp":1323872053000},"page":"472-483","source":"Crossref","is-referenced-by-count":23,"title":["Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab"],"prefix":"10.1016","volume":"39","author":[{"given":"Beom-Su","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung Sub","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faezeh","family":"Razjouyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shutao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengsheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang H.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0005","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0360-3016(93)90391-8","article-title":"Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells","volume":"27","author":"Macklis","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/10849780152389401","article-title":"Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy","volume":"16","author":"Kroger","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0015","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0020","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/cncr.22066","article-title":"Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma","volume":"107","author":"Weigert","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0030","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2r-alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0035","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ijrobp.2006.06.038","article-title":"Cure of incurable lymphoma","volume":"66","author":"DeNardo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0040","first-page":"1447","article-title":"Phase I study of intravenous Lu-177-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma","volume":"1","author":"Mulligan","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0045","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1200\/JCO.1996.14.6.1798","article-title":"Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics","volume":"14","author":"Yu","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0050","first-page":"1720","article-title":"Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3","volume":"6","author":"Pai-Scherf","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0055","first-page":"4478","article-title":"Interstitial pressure-gradients in tissue-isolated and subcutaneous tumors \u2014 implications for therapy","volume":"50","author":"Boucher","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0060","first-page":"1191","article-title":"A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier","volume":"31","author":"Fujimori","year":"1990","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0065","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.1073\/pnas.92.19.8999","article-title":"Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier","volume":"92","author":"Saga","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0070","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1535-7163.1493.3.11","article-title":"Biological impediments to monoclonal antibody-based cancer immunotherapy","volume":"3","author":"Christiansen","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0075","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","article-title":"Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation","volume":"13","author":"Jain","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0080","doi-asserted-by":"crossref","first-page":"17099","DOI":"10.1073\/pnas.0708101104","article-title":"Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02656730400011032","article-title":"Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: application of the thermal equivalency equation","volume":"21","author":"Hauck","year":"2005","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2967\/jnumed.107.046888","article-title":"Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice","volume":"49","author":"Khaibullina","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0095","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1073\/pnas.78.9.5608","article-title":"Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores","volume":"78","author":"De Brabander","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0163-7258(84)90025-1","article-title":"Taxol: an antimitotic agent with a new mechanism of action","volume":"25","author":"Manfredi","year":"1984","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0105","first-page":"687","article-title":"Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits","volume":"9","author":"Moos","year":"1998","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0110","first-page":"1851","article-title":"Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway","volume":"56","author":"Blagosklonny","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/mcbr.1999.0146","article-title":"A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis","volume":"2","author":"Oyaizu","year":"1999","journal-title":"Mol Cell Biol Res Commun"},{"issue":"Suppl 2","key":"10.1016\/j.nucmedbio.2011.10.020_bb0120","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/annonc\/mdn072","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Kataja","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0125","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","article-title":"Third consensus on medical treatment of metastatic breast cancer","volume":"20","author":"Beslija","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0130","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0135","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1073\/pnas.94.8.4000","article-title":"Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts","volume":"94","author":"DeNardo","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.10029","article-title":"Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6","volume":"50","author":"O'Donnell","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0145","first-page":"4613","article-title":"Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy","volume":"23","author":"Blumenthal","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0150","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2005.12.004","article-title":"Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts","volume":"102","author":"Masters","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0155","first-page":"716","article-title":"Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model","volume":"47","author":"Kelly","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0160","doi-asserted-by":"crossref","first-page":"7158s","DOI":"10.1158\/1078-0432.CCR-1004-0012","article-title":"Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers","volume":"11","author":"Miers","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0165","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.2005.08.119","article-title":"Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications","volume":"23","author":"Taghian","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0170","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0180","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0185","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<741::AID-CNCR13>3.0.CO;2-T","article-title":"Angiogenesis in endometrial carcinoma","volume":"80","author":"Kaku","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0190","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0002-9378(96)70224-7","article-title":"Angiogenesis factor in endometrial carcinoma: a new prognostic indicator?","volume":"174","author":"Kirschner","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0195","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0200","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ejca.2008.01.005","article-title":"The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab","volume":"44","author":"Marty","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0205","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0215","author":"Genentech, Inc"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0220","author":"F. Hoffmann-La Roche Ltd"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0225","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0230","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","article-title":"Combination of antiangiogenesis with chemotherapy for more effective cancer treatment","volume":"7","author":"Ma","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0235","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1078-0432.743.11.2","article-title":"Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment","volume":"11","author":"Ansiaux","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0240","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-06-2441","article-title":"Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization","volume":"13","author":"Dings","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0245","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cncr.24792","article-title":"Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma","volume":"116","author":"Salaun","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0250","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/annonc\/mdq122","article-title":"Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer","volume":"21","author":"Chan","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0255","first-page":"3781","article-title":"Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas","volume":"51","author":"Pastan","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0260","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/BF00285586","article-title":"Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)","volume":"21","author":"Camera","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0265","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0969-8051(93)90096-D","article-title":"Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts","volume":"20","author":"Camera","year":"1993","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0270","first-page":"5755","article-title":"Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N\",N\"'-tetraacetic acid (DOTA)-biotin","volume":"62","author":"Yao","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0275","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jnci\/djj070","article-title":"Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers","volume":"98","author":"Dreher","year":"2006","journal-title":"J Natl Cancer I"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0280","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bjc.6604429","article-title":"Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model","volume":"99","author":"Bozec","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0285","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","article-title":"Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice","volume":"12","author":"Zhang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0290","first-page":"2862","article-title":"Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents","volume":"7","author":"Holden","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0295","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0300","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/jcbfm.2008.162","article-title":"Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model","volume":"29","author":"Varallyay","year":"2009","journal-title":"J Cerebr Blood F Met"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0305","first-page":"3776","article-title":"Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications","volume":"59","author":"Griffon-Etienne","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0310","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0315","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0320","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s13139-010-0047-7","article-title":"Radiation safety issues in Y-90 microsphere selective hepatic radioembolization therapy: possible radiation exposure from the patients","volume":"44","author":"Kim","year":"2010","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0325","first-page":"1224","article-title":"Biodistribution and therapeutic efficacy of (125\/131)I-, (186)Re-, (88\/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin","volume":"45","author":"Koppe","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.10.020_bb0330","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805111002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805111002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T20:45:36Z","timestamp":1686516336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805111002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0969805111002538"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.10.020","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}